Bioatla (BCAB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
15 Jan, 2026Executive summary
A special meeting of stockholders is scheduled to reconvene virtually on January 26, 2026, to vote on a reverse stock split proposal for common stock at a ratio between 1-for-5 and 1-for-20, at the board's discretion prior to June 30, 2026.
Previous meetings approved the issuance of 20% or more of outstanding common stock under certain agreements and the ability to adjourn meetings to solicit additional proxies.
The board unanimously recommends voting in favor of the reverse stock split proposal.
Voting matters and shareholder proposals
The main proposal is to amend the certificate of incorporation to effect a reverse stock split within a specified range, with the exact ratio determined by the board.
Stockholders previously approved the stock issuance proposal and the adjournment proposal; only the reverse stock split proposal remains for consideration.
Approval of the reverse stock split requires an affirmative vote of two-thirds of the voting power present at the meeting.
Proxies previously submitted for the original meeting will be used unless revoked, and stockholders can change their vote before the reconvened meeting.
Board of directors and corporate governance
The board authorized the issuance of a Super-Voting Share to the CEO, which mirrors the common stock vote and is only used for the reverse stock split proposal.
Only stockholders of record as of January 12, 2026, are entitled to vote at the reconvened meeting.
Latest events from Bioatla
- Stockholders to vote on a merger and share conversion at a reconvened meeting on March 23, 2026.BCAB
Proxy Filing2 Mar 2026 - Shareholders to vote on a 1-for-50 share consolidation to address Nasdaq listing compliance.BCAB
Proxy Filing11 Feb 2026 - Q2 2024 saw reduced net loss, clinical milestones, and cash runway through Q3 2025.BCAB
Q2 20242 Feb 2026 - Promising clinical data and pivotal trial plans drive optimism for CAB-based cancer therapies.BCAB
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Vote on a 1-for-50 share consolidation merger to regain Nasdaq compliance and update governance.BCAB
Proxy Filing30 Jan 2026 - iNKT cell therapies show promise in cancer and ARDS, with pivotal trials and new programs underway.BCAB
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Up to $200M in securities offered, with $18.75M in equity deals to fund R&D and operations.BCAB
Registration Filing16 Jan 2026 - Q3 2024 saw clinical progress, reduced losses, and a licensing deal extending cash runway to 2026.BCAB
Q3 202415 Jan 2026 - Stockholders are urged to vote on a board-discretionary reverse stock split by January 12, 2026.BCAB
Proxy Filing31 Dec 2025